Welcome to the Definitive Industry Forum for Spearheading Cellular Therapies for Autoimmune Indications
We joined industry trailblazers to seize novel opportunities at the 2nd Cell Therapy for Autoimmune Disease Summit as the only meeting focused on developing safe, efficacious, affordable, and curative cell-based therapies for autoimmune patients to transform their treatment!
We got involved in this unmissable summit to learn and connect with pioneers including Cartesian Therapeutics, the University of Pennsylvania, Bristol Myers Squibb, Novartis, and many more to troubleshoot safety concerns, showcase clinical advancements, understand long-term effects in autoimmune patients, and much more.
Whether your team was ahead of the curve and currently pursuing this approach, or if you were looking to gain deeper insights into this field to advance your current pipelines, this cutting-edge conference was designed to inspire and facilitate the brainstorming of best-in-class approaches for developing more effective cell-based treatment solutions for patients affected by autoimmune conditions.
We Attended the 2nd Cell Therapy for Autoimmune Disease Summit to:
1
Uncover the latest clinical results showcasing evidence of the benefit of cell therapies for autoimmune indications with BMS, Cabaletta Bio, and Quell Therapeutics.
2
Accelerate entry into the clinic through an understanding of preclinical results with Abata Therapeutics, Intellia Therapeutics, and Cincinnati Children’s Hospital Medical Center.
3
Optimize engineering of advanced cell therapies for stronger efficacy, potency, and reliable remission with Gentibio, Appia Bio, and Synaptimmune.
4
Lead the exploration of the long-term effects of cell therapies in autoimmune patients and the mechanisms behind these effects with iCell Gene, University of Tennessee and UT Health San Antonio.
5
Explore regulatory CMC and safety expectations when entering the autoimmune space with the Association for the Advancement of Blood & Biotherapies, Cartesian Therapeutics and IASO Biotherapeutics.
Who Was In The Room?
We connected with top cell therapy pioneers, clinicians, investors, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment.
“Good mix of clinical, research, and commercial topics led by leaders in the field with presence of the most relevant companies that are likely to generate the next wave of exciting clinical data in this space.”
Executive Director, Allogene Therapeutics, 2023 Attendee